Posted in | Nanomedicine | Nanobusiness

MultiCell Technologies Inks New Sponsored Research Agreement for Liver Cancer Treatment

Published on October 4, 2013 at 6:56 AM

MultiCell Technologies, Inc. is pleased to announce the signing of a new sponsored research agreement with Anand Ghanekar, M.D., Ph.D, of the University Health Network's Toronto General Hospital expanding the scope of the research project to evaluate MCT-485 in animal models for the treatment of primary liver cancer.

MCT-485 is a noncoding double stranded micro RNA (miRNA) which has demonstrated oncolytic and immune stimulating activity in in vitro models of hepatocellular carcinoma.

Under the terms of the new research agreement, Dr. Ghanekar will also evaluate a targeted nanoparticle version of MCT-485 for the treatment of liver cancer. The targeted nanoparticle version of MCT-485 is being developed in collaboration with Genisphere LLC, a DNA nanotechnology company. MultiCell is investigating the use of Genisphere's DNA nanoparticle drug delivery technology to enable the targeted delivery of MCT-485 to the tumor and away from normal tissues.

Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death worldwide with over 1 million cases reported annually. Hepatocellular carcinoma remains an unmet medical need, and today's approaches for treatment are of limited efficacy. MCT-485, possessing both oncolytic and immune activating properties, could be superior to doxorubicin, cisplatin and other currently marketed therapies by providing a more robust activation of immunity, and a more global and longer lasting anti-tumor effect.

About MCT-485

MultiCell Technologies' MCT-485 is a noncoding double stranded micro RNA (miRNA), and the first of a family of prospective cancer therapeutics based on the use of our patented TLR3 signaling technology. MultiCell owns rights to several issued U.S. and foreign patents and patent applications related to MCT-485. The mechanism of action of MCT-485 is pleiotropic:

  • Induction of tumor cell death upon direct exposure, while normal cells are minimally affected.
  • Production of TNF-alpha by cancer cells resulting in amplified tumor cell death and a localized immune reaction that has the potential to generalize and curb progression of metastatic cancer.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. For more information about MultiCell Technologies, please visit multicelltech.com.

Source: http://www.multicelltech.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit